In major depression, increased serum dynorphin and kappa opioid receptor levels are positively associated with mu opioid receptor levels and immune activation and are attenuated by nicotine dependence.
Introduction
Major depressive disorder (MDD) is a chronic relapsing disorder characterized by the recurrence of major depressive episodes. A recent meta-analysis reported that, from 1994 to 2014, the lifetime prevalence of depression was 10.8% (1) . There is now evidence that MDD is associated with changes in immune functioning and activation of immune-inflammatory pathways comprising increased production of pro-inflammatory (e.g. interleukin-6 (IL-6)) as well as immune regulatory (e.g.. IL-10) mediators (2, 3, 4, 5, 6, 7, 8) . The latter are part of a regulatory system that down-regulates the primary immune-inflammatory response via multiple negative feedback systems, collectively named the "compensatory immune regulatory system" (CIRS) (8, 9) .
Aberrations in endogenous opioid peptides and their receptors are other characteristics of MDD. The opioid system comprises three families of neuropeptides, namely endorphins, enkephalins, and dynorphins, and three cognate receptor subtypes, namely μ (MOR), δ (DOR), and κ (KOR) receptors (10) . β-Endorphin and enkephalins bind to MORs and DORs, while dynorphin bind predominately to KORs (11) . Both opioid receptors and opioid peptides are expressed throughout peripheral and central nervous systems (12) . A growing body of research indicates that those endogenous opioids and their receptors are involved in emotional and behavioral responses to stress, regulation of mood and the pathophysiology of MDD (13, 14) .
MOR is a key component of reward processing, while acute activation of MOR attenuates depressive-like behaviors in some but not all studies (15) . MDD is accompanied by increased baseline and post-dexamethasone β-endorphin concentrations (2, 16, 17, 18) . In animal models, increased β-endorphin secretion is associated with depressive-like behaviors suggesting that the opioid system could be a new drug target to treat depression (19) . Recently, we reported that MOR levels were significantly higher in MDD patients than controls (13) , while post-mortem studies showed increased MOR binding in suicide victims (20) . Positron emission tomography (PET), on the other hand, showed contradictory results with increased binding potential for [ 11 C ]-carfentanil during depression, but decreased biding potential in women with MDD (21) .
A variety of stressors may increase KOR signaling, which is implicated in stress-induced changes in brain reward systems, which, in turn, may contribute to despair-and depression-like responses and depressive disorders (15, 22, 23, 24, 25) . As such, some authors regard KOR signaling as an anti-reward dysphoric system increasing risk towards depression (26, 27) . The overall conclusion from animal models supports the idea that the KOR system may underpin aspects of sadness and dysphoria but that the cause of the opioid alterations in MDD remains inconclusive (28) . Nevertheless, in a pilot study, no differences in KOR binding (using [11C]GR103545) could be found between MDD patients and controls (29), while prodynorphin mRNA was significantly lower in MDD and bipolar depression as compared with controls (30).
There is now evidence that immune and opioid systems show functional relationships. T and B-lymphocytes, granulocytes, and monocytes/macrophages express opioid peptides, including β-endorphin and pro-opiomelanocortin (POMC) and all POMC processing enzymes (31, 32). Opioid peptides are synthesized in circulating leukocytes that, directed by chemokines and adhesion molecules, may migrate to inflamed tissues where they may exert immune stimulatory as well as immune inhibitory activities (32,33). β-endorphin and dynorphin peptides modulate functions of lymphocytes and other cells involved in host defense and immunity (34).
Associations between both systems are also detected in patients with MDD. For example, lowered cell-mediated hypersensitivity and natural killer (NK) activity are significantly associated with increased β-endorphin levels in depression (32, 35). Castilla et al. (1992) reported an increased opioid tone in depression and a concomitant suppression of monocytic functions (36). Recently, we reported significant associations between MOR levels and IL-10 in patients with major depression (13) . Nevertheless, the associations between immune activation and the KOR/dynorphin system were not studied in patients with MDD.
There is also a strong comorbidity between MDD and tobacco use (NU) or nicotine dependence (ND) with increased inflammatory potential and affiliated nitro-oxidative pathways in comorbid MDD and NU/ND (37, 38, 39). Nicotine has a biphasic effect on the opioid system with anti-opioid effects at lower doses, while nicotine administration may entrain opioid activity "during the acquisition and re-acquisition of nicotine self-administration" (40). Nevertheless, the effects of comorbid MDD and ND on the KOR system has not been examined.
Hence, the present study was carried out to delineate a) serum IL-6 and IL-10 levels in association with the KOR/Dynorphin and MOR/endorphin systems in MDD patients as compared with healthy controls; and b) examine the effects of comorbid MDD and ND on these associations.
Subjects and Methods

Participants
The present study recruited 60 drug-free male participants with MDD aged 24-70 year and 30 age-matched healthy males as a control group. Participants were recruited at "The Psychiatry Unit", Al-Hakeem General Hospital and at a private psychiatric clinic, Najaf
Governorate, Iraq during the period of January to July 2017. This study reports KOR and dynorphin values in the same study group on which we published MOR, β-endorphin, IL-6 and IL-10 data (13), except that one patient and one control were substituted by two new cases with dynorphin/KOR measurements. The diagnosis was made using criteria of the 4 th edition of
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) [American Psychiatric
Association 2000]. Severity of depressive symptoms was assessed using the 24-item Hamilton Depression Rating Scale (HDRS) one or two days before blood was drawn. Only patients with a total HDRS score >21 were enrolled in the present study. Patients were divided in those with and without ND and all ND patients showed heavy nicotine use of more than 20 cigarettes/day.
Patients were evaluated using a full medical history. We excluded subjects with systemic disease that may affect immune parameters, including diabetes mellitus, autoimmune disorders, neuroinflammatory disorders, inflammatory bowel disorder, and chronic kidney disease. We also excluded subjects with neurodegenerative/neuroinflammatory disease including stroke, multiple and CUSABIO Co, China). We followed exactly all procedures according to the manufacturer's instructions. The intra-assay coefficients of variation (CV) (precision within-assay) were < 7.0%
for all analytes.
Statistical analysis
Differences in scale variables between diagnostic groups were examined using analysis of variance (ANOVA). Associations between nominal variables were assessed using analysis of IL6-IL10: index of immune activation computed as zIL-6 + zIL-10. Table 1 shows the socio-demographic data as well as the raw values of the biomarkers used in this study. Patients were divided into those with (MDD+ND) and without nicotine dependence (MDD). There were no significant differences in age, BMI and urban/rural ratio between the three study groups. There were somewhat more married subjects in MDD+ND than in controls, while there were more unemployed people in both depressed subgroups than in
Results
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controls. This Table also shows the raw measurements (not adjusted for extraneous variables) of the different biomarkers. Figure 1 shows the differences in biomarker profile between the three study groups. Shown are the group mean values (±SE) after z transformations were made. The BDI-II score was not significantly different between both MDD subgroups. Figure 2 shows the association between KOR and IL6-IL10, while Figure 3 shows the correlation between DYN-END and IL6-IL10. Figure 4 shows the association between KOR-MOR and IL6-IL10. Table 3 shows the outcome of a multivariate GLM analysis with the 10 biomarkers as dependent variables while adjusting for age and BMI. The dependent variables were DYN, END, KOR, MOR, IL-6, and IL-10 levels as well as z unit weighed composite scores, namely DYN-KOR, DYN-END, KOR-MOR and IL6-IL10. We found a highly significant effect of diagnosis with an effect size of 0.483, while age and BMI were not significant. There were highly significant associations between all 10 biomarkers and diagnosis with the strongest associations between diagnosis and IL6-IL10, END, DYN-END, IL-10 and KOR-MOR (with effect sizes > 0.300). Table 4 shows the model-generated estimated marginal mean values (in z scores) obtained by the GLM analyses shown in Table 3 . Pair-wise multiple post-hoc analyses showed that DYN was significantly higher in MDD as compared with controls and MDD+ND. KOR, DYN-KOR and DYN-END were significantly different between the three study groups and increased from controls  MDD+ND  MDD. END, MOR, KOR-MOR, IL-6, IL-10 and IL6-IL10 were significantly higher in both MDD groups than in controls. 
Biomarker differences between controls and patients groups
Discussion
The first major finding of this study is that serum dynorphin and KOR were significantly increased in MDD as compared with controls and that increases in those opioid peptides and their receptors are interrelated, suggesting that dynorphin/KOR signaling is significantly increased in MDD. However, two previous clinical studies were unable to observe signs of increased dynorphin/KOR signaling in depression (see introduction: 29, 30). As described in the Introduction, increased KOR signaling results in anti-reward and dysphoric effects thereby contributing to depressive behaviors (15, 22, 23, 24, 25, 26, 27 (45) . KORs are also involved in the regulation of serotonergic (42) and noradrenergic (46) and IL-6 may stimulate hypothalamic corticotrophin releasing hormone (CRH) release (2, 54) . In response to CRH and cytokines, peripheral blood mononuclear cells may secrete opioids (33). Nevertheless, the major sources of local endogenous opioid ligands including β-endorphin and dynorphin are leukocytes (55) . For example, in macrophages, monocytes, granulocytes and lymphocytes, β-endorphin is present in secretory granules arranged at the cell periphery ready for exocytosis (11) . Quantitative analysis revealed that in early inflammation, granulocytes (especially neutrophils) are the major opioid-containing leukocytes, whereas in later stages of inflammation, monocytes or macrophages and lymphocytes (especially activated T and B cells) predominate (56, 57) . Therefore, leukocytes are able to exert analgesic effects by releasing opioid peptides which bind to opioid receptors of the nociceptors in the periphery (11) .
Dynorphins produced during inflammatory conditions display anti-inflammatory effects by attenuating translocation of nuclear factor-ΚB and consequently production of tumor necrosis factor-α and IL-1β (58). Inhibition of nuclear-factor ΚB is likely a major mechanism explaining the anti-inflammatory effects of opioids (58) . Also, activation of KOR by dynorphins negatively regulates many immune cell functions including cytokine production by macrophages (59) The third major finding of this study is that KOR and the index dynorphin/KOR signaling are both significantly decreased in MDD subjects with comorbid nicotine dependence, while there are no significant effects on β-endorphin or MOR levels (although there is a trend towards a decrease). Smoking is highly prevalent among people with MDD (73) and is commonly cited as a means to cope with depressed mood and counteract fatigue and inactivity (74) . As explained in the introduction, smoking is also a risk factor for depression through activated immune- (76) and, therefore, one possibility is that the lowered dynorphin/KOR levels in comorbid MDD and nicotine use may be due to dopamine release in response to nicotine. Moreover, KOR activation may attenuate the reinforcing effects of nicotine (77), while KOR agonists attenuate nicotine-induced locomotor activity (78) . Additionally, mice lacking the prodynorphin gene compared to wild-type mice self-administered nicotine at lower doses, suggesting that the dynorphin/KOR system plays an inhibitory role in the reinforcing effects of nicotine (79) . Therefore, it is aslo possible that MDD patients with releatively lower dynorphin/KOR signaling display increased reinforcement effects of nicotine and thus more nicotine dependence behaviors.
Furthermore, due to lowered dynorphin/KOR signaling, heavy smokers may show lowered antiinflammatory protection and, therefore, may be more vulnerable to the detrimental effects of smoking-induced IL-6 and TNF-α signaling (73, 80, 81) .
Limitations of the study
The results of this study should be discussed with respect to its limitations. One limitation is that it would have been more interesting if we had measured many more cytokines including those produced by M1 macrophage, T helper (Th)-1, Th-2, Th-17 and T regulatory phenotypes in order to examine the associations of opioids with the full spectrum of IRS and CIRS cytokines and their ratios (8) . Secondly, this study examined male subjects only and therefore our study should be replicated in females. IL6-IL10: index of immune activation computed as z interleukin-6 (zIL6) + zIL10 Table 4 : Model-generated estimated marginal means of the 10 biomarkers obtained by GLM analysis shown in Table 2 in controls (HC) and major depressed (MDD) patients, divided into those with (MDD+ND) and without (MDD) nicotine dependence. 
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